Journal
JOURNAL OF MEDICINAL CHEMISTRY
Volume 62, Issue 21, Pages 9618-9641Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.9b01032
Keywords
-
Categories
Ask authors/readers for more resources
Nonselective antagonists of voltage-gated sodium (Na-V) channels have been long used for the treatment of epilepsies. The efficacy of these drugs is thought to be due to the block of sodium channels on excitatory neurons, primarily Na(V)1.6 and Na(V)1.2. However, these currently marketed drugs require high drug exposure and suffer from narrow therapeutic indices. Selective inhibition of Na(V)1.6, while sparing Na(V)1.1, is anticipated to provide a more effective and better tolerated treatment for epilepsies. In addition, block of Na(V)1.2 may complement the anticonvulsant activity of Na(V)1.6 inhibition. We discovered a novel series of aryl sulfonamides as CNS-penetrant, isoform-selective Na(V)1.6 inhibitors, which also displayed potent block of Na(V)1.2. Optimization focused on increasing selectivity over Na(V)1.1, improving metabolic stability, reducing active efflux, and addressing a pregnane X-receptor liability. We obtained compounds 30-32, which produced potent anticonvulsant activity in mouse seizure models, including a direct current maximal electroshock seizure assay.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available